Kelley Kenneth J 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Feb 1, 2021
Insider Transaction Report
Form 4
Kelley Kenneth J
Director
Transactions
- Sale
Common Stock
2021-02-01$48.69/sh−246$11,977→ 189,833 total - Sale
Common Stock
2021-02-01$48.09/sh−4,754$228,617→ 190,079 total
Footnotes (3)
- [F1]This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Represents a weighted average sales price per share. These shares were sold at prices ranging from $47.64 to $48.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold at prices ranging from $48.65 to $48.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.